BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

253 related articles for article (PubMed ID: 31680408)

  • 21. Diffuse Uveal Melanocytic Proliferation With Primary Vitreoretinal Lymphoma.
    Leskov I; Lyon AT; Jampol LM
    JAMA Ophthalmol; 2019 Jul; 137(7):834-837. PubMed ID: 31046111
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Clinical review: treatment of vitreoretinal lymphoma.
    Pe'er J; Hochberg FH; Foster CS
    Ocul Immunol Inflamm; 2009; 17(5):299-306. PubMed ID: 19831557
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Intravitreal methotrexate as an adjunctive treatment of intraocular lymphoma.
    Fishburne BC; Wilson DJ; Rosenbaum JT; Neuwelt EA
    Arch Ophthalmol; 1997 Sep; 115(9):1152-6. PubMed ID: 9298056
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Tumor Control and Visual Acuity Outcomes in Vitreoretinal Lymphoma with and without Sub-Retinal Pigment Epithelium Infiltration: Analysis of 125 Eyes of 70 Patients at a Single Ocular Oncology Center.
    Dalvin LA; Lim LS; Ancona-Lezama D; Mazloumi M; Chang M; Mashayekhi A; Shields CL
    Ophthalmol Retina; 2019 Nov; 3(11):998-1005. PubMed ID: 31358444
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Primary vitreoretinal natural killer/T-cell lymphoma with breast involvement: A case report and review of the literature.
    Gao S; Zhou Y; Jin X; Lin Z; Zhong Y; Shen X
    Surv Ophthalmol; 2019; 64(2):225-232. PubMed ID: 30321569
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Intravitreal rituximab monotherapy for management of eyes with vitreoretinal lymphoma: initial experience from India.
    Rishi P; Manchegowda PT; Gondhale HP; Rishi E; Das K; Krishnakumar S; Raja T; Biswas J
    Int Ophthalmol; 2021 Jul; 41(7):2495-2504. PubMed ID: 33730314
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Intravitreal Melphalan for Treatment of Primary Vitreoretinal Lymphoma: A New Indication for an Old Drug.
    Shields CL; Sioufi K; Mashayekhi A; Shields JA
    JAMA Ophthalmol; 2017 Jul; 135(7):815-818. PubMed ID: 28617918
    [No Abstract]   [Full Text] [Related]  

  • 28. Changes in choroidal vascular structure from vitreoretinal lymphoma and the intraocular cytokine level associated with clinical resolution after intravitreal methotrexate treatment.
    Kim RY; Park JH; Kim M; Park YG; Cho SG; Park YH
    PLoS One; 2021; 16(11):e0260469. PubMed ID: 34813633
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Association between ocular findings and preventive therapy with onset of central nervous system involvement in patients with primary vitreoretinal lymphoma.
    Hashida N; Nakai K; Saitoh N; Nishida K
    Graefes Arch Clin Exp Ophthalmol; 2014 Apr; 252(4):687-93. PubMed ID: 24549401
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Eyewash with balanced salt solution after intravitreal methotrexate injection in a case of vitreoretinal lymphoma: a simple but effective way to prevent ocular surface toxicity.
    Moharana B; Parija S; Palanisamy S; Mishra P
    BMJ Case Rep; 2023 Jul; 16(7):. PubMed ID: 37474142
    [TBL] [Abstract][Full Text] [Related]  

  • 31. First observation of intraocular extranodal natural killer/T-cell lymphoma secondary to a retroperitoneal tumour: a case report and comparative review.
    Chen B; Yang S; Su W
    BMC Ophthalmol; 2022 Mar; 22(1):141. PubMed ID: 35346113
    [TBL] [Abstract][Full Text] [Related]  

  • 32. CLINICAL FEATURES, DIAGNOSTIC SIGNIFICANCE, AND PROGNOSIS OF VITREORETINAL LYMPHOMA IN YOUNG PATIENTS.
    Liu S; Gu J; Zhang T; Ping B; Zhou M; Huang X; Jiang R; Xu G; Chang Q
    Retina; 2021 Dec; 41(12):2596-2604. PubMed ID: 34173362
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Intravenous high-dose methotrexate based systemic therapy in the treatment of isolated primary vitreoretinal lymphoma: An LOC network study.
    Lam M; Touitou V; Choquet S; Cassoux N; Ghesquières H; Kodjikian L; Schmitt A; Gattoussi S; Tabouret É; Sampo M; Blonski M; Angioi-Duprez K; Houot R; Mouriaux F; Gyan E; Le Lez ML; Moles MP; Croisé F; Chauchet A; Schwartz C; Ahle G; Meyer L; Gressin R; Chiquet C; Oberic L; Ollé P; Marolleau JP; Jany B; Tempescul A; Cochener B; Damaj G; Quintyn JC; Moluçon-Chabrot C; Rousseau E; Franciane P; Schneider C; Massé H; Tamburini-Bonnefoy J; Brézin A; Fornecker LM; Ballonzoli L; Le Garff-Tavernier M; Hoang-Xuan K; Bodaghi B; Soussain C; Houillier C
    Am J Hematol; 2021 Jul; 96(7):823-833. PubMed ID: 33864703
    [TBL] [Abstract][Full Text] [Related]  

  • 34. An Asian patient with intraocular lymphoma treated by intravitreal methotrexate.
    Wang JK; Yang CM; Lin CP; Shan YD; Lo AY; Tien HF
    Jpn J Ophthalmol; 2006; 50(5):474-478. PubMed ID: 17013703
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Treatment of primary intraocular lymphoma with intravitreal methotrexate.
    Sou R; Ohguro N; Maeda T; Saishin Y; Tano Y
    Jpn J Ophthalmol; 2008; 52(3):167-174. PubMed ID: 18661266
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Use of intravitreal rituximab and methotrexate in vitreoretinal lymphoma.
    Rahhal-Ortuño M; Udaondo-Mirete P; Fernández-Santodomingo AS; Díaz-Llopis M
    Eur J Ophthalmol; 2022 Jan; 32(1):NP199-NP202. PubMed ID: 32985253
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Primary intraocular lymphoma.
    Sagoo MS; Mehta H; Swampillai AJ; Cohen VM; Amin SZ; Plowman PN; Lightman S
    Surv Ophthalmol; 2014; 59(5):503-16. PubMed ID: 24560125
    [TBL] [Abstract][Full Text] [Related]  

  • 38. High-dose methotrexate following intravitreal methotrexate administration in preventing central nervous system involvement of primary intraocular lymphoma.
    Akiyama H; Takase H; Kubo F; Miki T; Yamamoto M; Tomita M; Mochizuki M; Miura O; Arai A
    Cancer Sci; 2016 Oct; 107(10):1458-1464. PubMed ID: 27412324
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Longitudinal Analysis of Ocular Manifestation and Interleukin During Intravitreal Treatment of Vitreoretinal Lymphoma With Methotrexate.
    Gu J; Jiang T; Liu S; Chen X; Wang Z; Zhang P; Wang L; Jiang R; Huang X; Xu G; Chang Q
    Am J Ophthalmol; 2023 Jul; 251():189-196. PubMed ID: 36963600
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Primary Vitreoretinal Lymphoma Therapy Monitoring: Significant Vitreous Haze Reduction After Intravitreal Rituximab.
    Kakkassery V; Heindl LM; Rokohl AC; Chronopoulos A; Schutz JS; Ranjbar M; Schargus M; Böker A; Winterhalter S; Stübiger N
    Neurosignals; 2021 May; 29(S1):1-7. PubMed ID: 33945240
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.